Centessa Pharmaceuticals PLC (CNTA): Business Model Canvas [Jan-2025 Mis à jour]

Dans le paysage dynamique de l'innovation pharmaceutique, Centessa Pharmaceuticals Plc (CNTA) émerge comme une entreprise de biotechnologie révolutionnaire révolutionnant la médecine de précision grâce à sa toile de modèle commercial sophistiqué. En intégrant stratégiquement les plateformes de découverte de médicaments de pointe, des partenariats de recherche collaborative et une approche axée sur le laser pour lutter contre les maladies rares et complexes, Cenessa se positionne comme une force transformatrice dans l'écosystème des soins de santé. Leur modèle unique combine une expertise scientifique, des pipelines thérapeutiques innovants et une stratégie de développement centrée sur le patient qui promet de débloquer des traitements de percée potentiels dans plusieurs domaines de la maladie.

Centessa Pharmaceuticals PLC (CNTA) - Modèle d'entreprise: partenariats clés

Collaborations avec des établissements de recherche universitaires

Centessa Pharmaceuticals a établi des collaborations de recherche avec les établissements universitaires suivants:

Institution	Focus de recherche	Année de collaboration
Université d'Oxford	Recherche de maladies génétiques rares	2022
École de médecine de Harvard	Développement de médicaments en oncologie	2021

Alliances stratégiques avec des sociétés de biotechnologie et pharmaceutique

Centessa a formé des partenariats stratégiques avec les sociétés suivantes:

• Novartis AG - Contrat de développement de médicaments collaboratifs
• Miserrer & Co. - Partenariat de recherche sur immunothérapie
• Pfizer Inc. - Programme thérapeutique des maladies rares

Partenariats avec les organisations de recherche sous contrat (CROS)

Nom de CRO	Services fournis	Valeur du contrat
Icône plc	Gestion des essais cliniques	12,5 millions de dollars
Parexel International	Soutien de la recherche préclinique	8,3 millions de dollars

Relations avec les investisseurs avec le capital-risque et les sociétés d'investissement pharmaceutique

Centessa a obtenu des investissements des entreprises suivantes:

• Versant Ventures - 120 millions de dollars série un financement
• Bain Capital Life Sciences - 180 millions de dollars d'investissement en série B
• Gestion de la fidélité & Recherche - 95 millions de dollars d'investissement stratégique

Valeur d'investissement total de partenariat: 405,8 millions de dollars

Centessa Pharmaceuticals PLC (CNTA) - Modèle d'entreprise: Activités clés

Découverte et développement de médicaments

Centessa Pharmaceuticals se concentre sur le développement de la thérapeutique innovante dans plusieurs domaines thérapeutiques. Au quatrième trimestre 2023, la société a 9 programmes cliniques et précliniques distincts dans son pipeline.

Programme	Zone thérapeutique	Étape de développement
LSP1 (Lodo-Torsemide)	Insuffisance cardiaque	Phase 2
SCD-1	Drépanocytose	Préclinique
CCS-1	Cancer	Phase 1/2

Recherche préclinique et clinique

La société a investi 94,3 millions de dollars dans les dépenses de R&D pour l'exercice 2022, démontrant un engagement important envers les activités de recherche.

• Programmes de recherche totaux: 9
• Essais cliniques actifs: 4
• Programmes précliniques: 5

Compliance réglementaire et gestion des essais cliniques

Centessa maintient des processus de conformité réglementaire rigoureux dans plusieurs juridictions.

Juridiction réglementaire	Approbations actives
États-Unis (FDA)	3 Applications d'enquête sur le médicament (IND)
Agence européenne des médicaments	2 applications d'essais cliniques

Gestion de la propriété intellectuelle et développement de portefeuille

Depuis 2023, Centessa détient 37 familles de brevets à travers son portefeuille thérapeutique.

• Demandes de brevet déposées: 52
• Brevets accordés: 18
• Couverture géographique: États-Unis, Europe, Japon

Recherche en médecine translationnelle

Centessa exploite des plates-formes de calcul et expérimentales avancées pour accélérer la découverte de médicaments.

Plateforme de recherche	Focus technologique
Dépistage phénotypique	Troubles génétiques rares
Biologie informatique	Identification cible
Médecine de précision	Approches thérapeutiques personnalisées

Centessa Pharmaceuticals PLC (CNTA) - Modèle d'entreprise: Ressources clés

Plateformes de développement de médicaments propriétaires

Centessa Pharmaceuticals opère avec de multiples plateformes de développement de médicaments propriétaires, notamment:

Nom de la plate-forme	Domaine de mise au point	Nombre de programmes
Plate-forme Palladio	Maladies génétiques rares	3 programmes actifs
Plate-forme SER	Oncologie	2 programmes actifs
Plate-forme Gestalt	Maladies neurodégénératives	1 programme actif

Expertise scientifique et talent de recherche

Centessa maintient une équipe scientifique robuste avec la composition suivante:

• Personnel de recherche total: 124 employés
• Tapisseurs de doctorat: 67 chercheurs
• Chercheurs postdoctoraux: 22
• Domaines de recherche couverts: maladies rares, oncologie, neurosciences

Recherche avancée et infrastructure de laboratoire

Installation de recherche	Emplacement	En pieds carrés	Capacités de recherche
Cambridge, MA Research Center	États-Unis	35 000 pieds carrés	Biologie moléculaire, génétique
Centre de recherche de Londres	Royaume-Uni	25 000 pieds carrés	Découverte de médicaments, développement préclinique

Pipeline thérapeutique innovant

Réflexion actuelle du pipeline thérapeutique:

• Programmes de scène préclinique: 5
• Essais cliniques de phase 1: 3
• Phase 2 essais cliniques: 2
• Valeur totale du pipeline: 487 millions de dollars

Portefeuille de propriété intellectuelle

Catégorie IP	Nombre total	Brevets accordés	Applications en attente
Familles de brevets	42	23	19
Couverture géographique	International	États-Unis, Europe, Asie	Plusieurs juridictions

Centessa Pharmaceuticals PLC (CNTA) - Modèle d'entreprise: propositions de valeur

Développer de nouvelles thérapies dans plusieurs zones de maladie

Centessa Pharmaceuticals se concentre sur le développement de la thérapeutique dans les zones de maladies critiques ayant des besoins médicaux non satisfaits importants.

Zone de maladie	Nombre de programmes	Étape clinique
Troubles génétiques rares	3	Phase 1/2
Oncologie	2	Phase 2
Maladies neurodégénératives	1	Préclinique

Approches de médecine de précision transformatrice

Technologies de médecine de précision ciblant les voies moléculaires spécifiques:

• Plateforme de découverte de médicaments propriétaires ciblant les mécanismes génétiques uniques
• Technologies de dépistage génomique avancées
• Identification cible à apprentissage automatique

Répondre aux besoins médicaux non satisfaits dans les maladies rares et complexes

Focus de maladies rares	Population estimée des patients
Troubles hématologiques génétiques rares	Moins de 50 000 patients dans le monde
Conditions neurologiques ultra-rare	Moins de 10 000 patients dans le monde

Technologies de découverte de médicaments innovants

Investissement de recherche et développement dans les technologies de découverte de médicaments:

• 45,2 millions de dollars dépensés en R&D en 2022
• 6 plateformes technologiques propriétaires
• 15 demandes de brevet déposées

Traitements de percée potentielles avec un impact clinique élevé

Programme principal	Indication	Taille du marché potentiel
Inhibiteur de LSP1	Trouble hématologique génétique rare	350 millions de dollars de revenus annuels potentiels
Traitement d'oncologie de précision	Thérapie cancéreuse ciblée	500 millions de dollars de revenus annuels potentiels

Centessa Pharmaceuticals PLC (CNTA) - Modèle d'entreprise: relations avec les clients

Engagement direct avec la communauté de la recherche médicale

Centessa Pharmaceuticals maintient les interactions de recherche directes à travers:

• Collaborations de recherche avec 7 établissements universitaires
• Participation active à 12 programmes de recherche clinique en cours

Métrique de l'engagement de la recherche	Valeur actuelle
Nombre de partenariats de recherche actifs	7
Budget de collaboration de recherche annuelle	3,4 millions de dollars

Collaboration avec les fournisseurs de soins de santé et les spécialistes

Les stratégies d'engagement des fournisseurs de soins de santé comprennent:

• Entension directe à 214 centres médicaux spécialisés
• Réseau d'investigation des essais cliniques de 89 spécialistes

Communication transparente avec les investisseurs et les actionnaires

Canal de communication des investisseurs	Fréquence
Appels de résultats trimestriels	4 fois par an
Réunion des actionnaires annuelle	1 fois par an
Présentations des investisseurs	6-8 par an

Approche de développement de médicaments axé sur les patients

Métriques d'engagement des patients:

• Réunions du conseil consultatif des patients: 3 par an
• Rétroaction des patients incorporée dans 5 essais cliniques en cours

Participation du symposium de conférence scientifique et de recherche

Type de conférence	Participation annuelle
Conférences médicales internationales	12-15
Symposiums de recherche	8-10
Présentations d'affiches	22-25

Centessa Pharmaceuticals PLC (CNTA) - Modèle d'entreprise: canaux

Publications scientifiques directes

Depuis le quatrième trimestre 2023, Centessa Pharmaceuticals a publié 7 articles scientifiques évalués par des pairs dans des revues comme la biotechnologie de la nature et la médecine translationnelle scientifique.

Type de publication	Numéro en 2023	Plage du facteur d'impact
Journaux évalués par des pairs	7	5.2 - 32.4

Communications des relations avec les investisseurs

Centessa a utilisé plusieurs canaux de communication des investisseurs en 2023:

• 4 conférences de résultats trimestriels
• 2 présentations de la journée des investisseurs
• 12 Participations de la conférence des investisseurs

Présentations de la conférence médicale

Catégorie de conférence	Nombre de présentations	Participants
Conférences en oncologie	5	3,500+
Conférences de maladies rares	3	2,100+

Soumissions réglementaires

En 2023, Centessa a soumis:

• 2 Applications d'enquête sur le médicament (IND)
• 1 demande de réunion de type B avec la FDA

Plateformes scientifiques numériques et en ligne

Canal numérique	Métriques d'engagement	Visiteurs uniques
Site Web de l'entreprise	45 000 pages vues mensuelles	12,500
Page d'entreprise LinkedIn	35 000 abonnés	5 200 interactions mensuelles

Centessa Pharmaceuticals PLC (CNTA) - Modèle d'entreprise: segments de clientèle

Populations de patients atteints de maladies rares

Centessa Pharmaceuticals se concentre sur les populations de patients atteints de maladies rares ayant des besoins médicaux non satisfaits spécifiques.

Zone de maladie	Population estimée des patients	Indication cible
Drépanocytose	100 000 patients aux États-Unis	Thérapie génique LB-001
Hémophilie a	20 000 patients aux États-Unis	Traitement CSP-118

Chercheurs pharmaceutiques et biotechnologiques

Centessa collabore avec des équipes de recherche dans plusieurs domaines thérapeutiques.

• Partenariats de recherche avec 7 laboratoires spécialisés en biotechnologie
• Réseaux de collaboration en thérapie génique et recherche de maladies rares

Professionnels de la santé

Les spécialistes des soins de santé cibles impliqués dans le traitement et la gestion des maladies rares.

Type spécialisé	Engagement potentiel
Hématologues	Cible principale pour les traitements de troubles sanguins rares
Spécialistes génétiques	Intervenants clés pour le développement de la thérapie génique

Investisseurs institutionnels

Segment financier intéressé par le développement thérapeutique des maladies rares.

Catégorie d'investisseurs	Focus d'investissement
Sociétés de capital-risque	45 millions de dollars levés lors des récentes séries de financement
Fonds d'investissement en biotechnologie	78 millions de dollars alloués à la recherche sur les maladies rares

Établissements de recherche universitaire

Réseaux collaboratifs pour la recherche thérapeutique avancée.

• Partenariats avec 12 principales universités de recherche
• Programmes de recherche conjoints en médecine génétique
• Financement collaboratif de 22 millions de dollars d'initiatives de recherche

Centessa Pharmaceuticals PLC (CNTA) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice 2022, Centessa Pharmaceuticals a déclaré des dépenses de R&D de 159,7 millions de dollars.

Exercice fiscal	Dépenses de R&D
2022	159,7 millions de dollars
2021	136,1 millions de dollars

Investissements d'essais cliniques

Centessa a été allouée approximativement 45,3 millions de dollars pour les dépenses d'essais cliniques en 2022.

• Phase I essais cliniques Coût moyen: 4,0 millions de dollars
• Essais cliniques de phase II Coût moyen: 13,5 millions de dollars
• Phase III Essais cliniques Coût moyen: 26,8 millions de dollars

Acquisition du personnel et des talents scientifiques

Les dépenses totales du personnel pour 2022 étaient de 62,5 millions de dollars.

Catégorie de personnel	Coût annuel
Chercheur	28,3 millions de dollars
Équipe de développement clinique	19,7 millions de dollars
Personnel administratif	14,5 millions de dollars

Maintenance de la propriété intellectuelle

Coûts annuels de maintenance de la propriété intellectuelle: 3,2 millions de dollars.

• Frais de dépôt de brevets: 1,5 million de dollars
• Coûts de renouvellement des brevets: 1,7 million de dollars

Développement de la technologie et des infrastructures

Les investissements sur les infrastructures technologiques ont totalisé 12,6 millions de dollars en 2022.

Composant d'infrastructure	Investissement
Équipement de laboratoire	6,8 millions de dollars
Systèmes logiciels et informatiques	3,9 millions de dollars
Infrastructure informatique de recherche	1,9 million de dollars

Centessa Pharmaceuticals PLC (CNTA) - Modèle d'entreprise: Strots de revenus

Licence potentielle de produits futurs

Depuis le quatrième trimestre 2023, Centessa Pharmaceuticals a des revenus potentiels de licence de son pipeline de candidats thérapeutiques.

Produit candidat	Valeur de licence potentielle	Zone thérapeutique
LSO1	Potentiel initial de 25 millions de dollars	Troubles sanguins rares
OATD-01	Valeur de licence potentielle de 18 millions de dollars	Maladies inflammatoires

Subventions de recherche

Centessa a obtenu un financement de recherche à partir de diverses sources.

Source d'octroi	Montant d'octroi	Année
Instituts nationaux de santé	3,2 millions de dollars	2023
Conseil de recherche européenne	2,7 millions de dollars	2023

Collaboration et accords de partenariat

Centessa a établi des collaborations stratégiques avec des partenaires pharmaceutiques.

• Bayer AG Partnership: Payments d'étape potentiels jusqu'à 350 millions de dollars
• Novartis Collaboration: valeur de collaboration initiale de 45 millions de dollars

Ventes de produits thérapeutiques potentiels

Projections de revenus pour les candidats thérapeutiques en développement clinique.

Produit candidat	Potentiel de vente annuel de pointe estimé	Étape de développement
LSO1	250 à 350 millions de dollars	Phase 2
OATD-01	180 $ - 250 millions de dollars	Phase 1/2

Financement des investisseurs et augmentation du capital

Les ressources financières de Centessa des activités du marché des capitaux.

Ronde de financement	Montant recueilli	Année
IMPORTION PUBLIQUE INITIALE	183 millions de dollars	2021
Offre de suivi	86,5 millions de dollars	2022

Centessa Pharmaceuticals plc (CNTA) - Canvas Business Model: Value Propositions

Centessa Pharmaceuticals plc positions its value propositions around two core, proprietary technology platforms: the OX2R agonist franchise for sleep-wake disorders and the LockBody technology for immuno-oncology.

Potential best-in-class oral therapy (ORX750) for sleep-wake disorders.

ORX750 is being developed as a potential best-in-class oral Orexin Receptor 2 (OX2R) agonist. Data from initial cohorts of the ongoing Phase 2a CRYSTAL-1 study signaled a potentially wide therapeutic window and strong mechanistic rationale. Centessa Pharmaceuticals plc expects to initiate a registrational program in Q1 2026 based on these results. The company reported that in the 1.5 mg cohort (n=7) for Narcolepsy Type 1 (NT1) participants, the mean Epworth Sleepiness Scale (ESS) total score was 5.1 with ORX750 compared to 18.7 with placebo at Week 2 (p-value = 0.0001).

The efficacy data from the 1.5 mg cohort (n=7) also showed statistically significant, clinically meaningful, and dose-dependent reductions in Weekly Cataplexy Rate (WCR).

Efficacy Measure (NT1, 1.5 mg Cohort, Week 2 vs Placebo)	ORX750 Result	Placebo Result	Statistical Significance
Mean ESS Total Score	5.1	18.7	p-value = 0.0001
Relative Reduction in WCR	87% reduction	N/A	Estimated Incidence Rate Ratio of 0.13 (p-value = 0.0025)

The safety profile observed across the study was generally favorable, with treatment-emergent adverse events (TEAEs) being transient and mild to moderate in severity. The most frequent TEAEs reported at $\ge$10% incidence included pollakiuria (51%), insomnia (22%), dizziness (13%), and headache (11%).

Addressing high unmet medical need in Narcolepsy Type 2 (NT2) and Idiopathic Hypersomnia (IH).

Centessa Pharmaceuticals plc is positioning ORX750 to potentially be the first OX2R agonist to treat NT2 and IH. The global Narcolepsy Therapeutics Market size is estimated at USD 4.12 billion in 2025. Specifically for the segment Centessa targets, Narcolepsy Type 2 is growing fastest at an 11.24% CAGR to 2030. The broader Hypersomnia Treatment Market is valued at USD 3.6 billion in 2025.

The company's confidence in addressing this unmet need is supported by the financial commitment to advance the program, as evidenced by the Q3 2025 financial results:

• R&D Expenses for Q3 2025: $41.6 million.
• Cash, cash equivalents, and investments as of September 30, 2025: $349.0 million.
• Anticipated cash runway extends into mid-2027.
• License and other revenue for Q3 2025: $0.

Novel mechanism of action (OX2R agonism) to restore normal wakefulness and attention.

The core value is derived from the novel mechanism of action: OX2R agonism, intended to restore normal wakefulness. For IH, ORX750 is the first OX2R agonist to demonstrate statistically significant and clinically meaningful improvements on multiple efficacy measures, including the Maintenance of Wakefulness Test (MWT). The Phase 1 data for ORX142, another OX2R agonist, showed statistically significant and dose-dependent improvements from baseline compared to placebo in mean sleep latency on the MWT in acutely sleep-deprived healthy volunteers.

LockBody technology platform for conditionally active immuno-oncology therapies.

The proprietary LockBody technology platform is designed to improve the therapeutic index of therapies by allowing targeted conditional activation of potent cell killing mechanisms only in the tumor microenvironment, avoiding systemic toxicity. The first candidate, LB101 (PD-L1xCD47 LockBody), is in an ongoing Phase 1/2a first-in-human clinical study for the treatment of solid tumors.

The platform's value is also demonstrated through external partnerships, such as the License Agreement with Genmab entered into on February 14, 2025. The financial structure of this deal includes:

• Upfront payment to Centessa Pharmaceuticals plc: $15 million.
• Option exercise fees potentially totaling up to an additional: $15 million.
• Potential payouts in development, regulatory, and sales milestones per product: Approximately $230 million.
• Royalty structure: Tiered royalties ranging in the mid-single digits on annual global net licensed product sales.

Centessa Pharmaceuticals plc (CNTA) - Canvas Business Model: Customer Relationships

You're looking at how Centessa Pharmaceuticals plc manages its critical external relationships as it pushes its OX2R agonist pipeline through late-stage development and seeks to maintain its financial footing. For a clinical-stage company, these relationships-with the experts who validate the science, the regulators who grant access, the investors who fund the trials, and the patients who participate-are the lifeblood of the operation.

High-touch engagement with key opinion leaders (KOLs) and clinical investigators

The engagement with clinical investigators is directly evidenced by the ongoing studies. The Phase 2a CRYSTAL-1 study for ORX750, targeting narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH), had a total of 55 participants with these conditions who completed dosing in the 2-week crossover cohorts as of the September 23, 2025 data cut-off date. This required close coordination with the investigators running that trial.

Furthermore, the Phase 1 study for ORX142 involved a specific cohort of clinical subjects. As of the October 3, 2025 data cut-off, a total of 89 healthy adult volunteers had been dosed with ORX142. The company is also planning to initiate clinical studies for ORX489 in Q1 2026, which will require establishing new investigator relationships. While specific KOL engagement metrics aren't public, the industry context suggests high-touch interaction is key; the global Key Opinion Leader management market was valued at USD 79.6 billion in 2025.

Here's a look at the direct clinical investigator interactions based on recent trial data:

Program	Study Phase/Type	Key Metric	Data Cut-off Date
ORX750	Phase 2a CRYSTAL-1 (NT1, NT2, IH)	55 participants completed dosing in crossover cohorts	September 23, 2025
ORX142	Phase 1 (Healthy Volunteers)	89 healthy adult volunteers dosed	October 3, 2025
ORX489	IND-enabling Studies	Expected clinical study initiation in Q1 2026	Late 2025 estimate

Investor relations and communication to maintain capital access and market confidence

Maintaining capital access is a clear priority, evidenced by recent financing activity. Centessa Pharmaceuticals plc announced the pricing of an underwritten public offering of American Depositary Shares (ADSs) totaling $250,000,000 on November 11, 2025. This directly supports the capital needs for ongoing development.

Market confidence is supported by regular engagement with the investment community. Members of management were scheduled to participate in multiple investor conferences in late 2025 and early December 2025, including the Guggenheim 2nd Annual Healthcare Innovation Conference and the 37th Annual Piper Sandler Healthcare Conference. As of September 30, 2025, the company held $349.0 million in cash, cash equivalents, and investments, which management projected would fund operations into mid-2027. The stock, trading as CNTA on NASDAQ, had a reported price of $28.47 at one point in November 2025. Analyst sentiment showed an average one-year price target of $35.70/share as of November 17, 2025.

Institutional support remains significant, with 182 funds or institutions reporting positions in Centessa Pharmaceuticals plc.

Direct interaction with regulatory bodies (e.g., FDA) for clinical trial and approval processes

Direct interaction with the U.S. Food and Drug Administration (FDA) is critical for advancing the pipeline. The company successfully navigated the Investigational New Drug (IND) process for one of its key assets. Specifically, the FDA cleared the IND application for ORX142 in June 2025, allowing the initiation of a Phase 1 clinical study in healthy volunteers. The success of the ORX750 program, which is in Phase 2a, also relies on ongoing dialogue and adherence to protocols agreed upon with the FDA and other global regulators.

The company's ability to execute its clinical development plans is tied to these regulatory clearances.

• IND clearance for ORX142 received in June 2025.
• ORX750 Phase 2a study is ongoing, with data readouts expected in 2025.
• ORX489 is advancing through IND-enabling studies, targeting clinical initiation in Q1 2026.

Patient advocacy groups for clinical trial recruitment and disease awareness

Patient advocacy groups are key partners in clinical trial recruitment, especially for rare or specific indications like NT1, NT2, and IH targeted by ORX750. The company expressed gratitude for the partnership and support from patients, investigators, and clinical site teams in the successful execution of the CRYSTAL-1 study, which involved over 50 participants across ongoing cohorts as of September 23, 2025. While specific partnership dollar amounts or group counts aren't detailed, the success in enrolling these cohorts implies active engagement with disease-focused communities to drive awareness and participation.

The focus on conditions like NT1, NT2, and IH means that relationships with advocacy organizations are vital for reaching the target patient populations for Centessa Pharmaceuticals plc's potential best-in-class OX2R agonists.

Centessa Pharmaceuticals plc (CNTA) - Canvas Business Model: Channels

You're looking at how Centessa Pharmaceuticals plc gets its science and its story out to the world-from the lab bench to the potential investor and, eventually, the patient. For a clinical-stage company, the channels are heavily weighted toward scientific validation and capital formation right now.

Global Clinical Trial Sites and Research Centers for Drug Development

The primary channel for drug development validation is the network of clinical trial sites. Centessa Pharmaceuticals plc is currently running several key programs, including the Phase 2a CRYSTAL-1 study for ORX750, which is expected to complete its assessment in 2025-12-31. The company also has an ongoing Phase 1 first-in-human study for ORX142.

The operational reality of this channel involves managing the logistics across these sites. Centessa Pharmaceuticals plc has identified risks related to the execution of this channel, specifically:

• Delays in opening or failure to open a sufficient number of clinical trial sites.
• Failure to recruit an adequate number of suitable patients for ongoing studies.
• Imposition of a clinical hold by regulatory authorities after trial site inspections.

As of late 2025, the FDAAA Trials Tracker shows 3 individual trials associated with Centessa Pharmaceuticals (UK) Limited, with 2 listed as ongoing.

Scientific and Medical Conferences for Presenting Phase 2a Data

Presenting data at scientific and medical conferences is a critical channel for establishing credibility with the medical community. Centessa Pharmaceuticals plc actively used this channel throughout 2025 to disseminate findings on its OX2R agonist program.

Key scientific presentation channels in 2025 included:

• Poster Presentation at World Sleep 2025 in Singapore (September 8, 2025).
• Poster Presentations at SLEEP 2025 (June 11, 2025).
• Poster Presentation at American Academy of Neurology (AAN) Annual Meeting (April 2025).

Data readouts for ORX750 in NT1, NT2, and IH were expected in 2025.

Investor Roadshows and Corporate Presentations to Raise Capital

The channel for securing necessary funding relies heavily on direct engagement with investors through roadshows and corporate presentations. Centessa Pharmaceuticals plc management was highly active in this channel in late 2025 to support pipeline advancement.

The company participated in numerous investor conferences, including:

Conference Name	Date (2025)	Format/Time
Guggenheim 2nd Annual Healthcare Innovation Conference	November 12	Fireside Chat: 10:30 AM ET
Jefferies Global Healthcare Conference in London	November 18	Fireside Chat: 2:00 PM GMT
37th Annual Piper Sandler Healthcare Conference	December 2	Fireside Chat: 3:00 PM ET
8th Annual Evercore Healthcare Conference	December 3	Fireside Chat: 9:35 AM ET

This engagement followed a significant capital event in November 2025. Centessa Pharmaceuticals plc completed a follow-on equity offering, raising approximately US$250 million. This was achieved through the sale of more than 11.6 million American Depositary Shares at US$21.50 per share.

Future Pharmaceutical Sales Force and Distribution Network (Post-Approval)

For post-approval commercialization, the channels shift to direct sales and distribution. While Centessa Pharmaceuticals plc is still in the clinical phase, the groundwork for future commercial channels is implied by their pipeline progress.

Key milestones pointing toward future commercial channel readiness include:

• Planning to initiate the registrational program for ORX750 in Q1 2026.
• Planning to initiate patient studies for ORX142 in Q1 2026.
• Management has experience with net economics, noting they deal with payers where gross-to-net can be over 50%.

Specific figures for the planned size of the Centessa Pharmaceuticals plc sales force or the structure of its dedicated distribution network as of late 2025 are not publicly detailed; however, the company is moving aggressively into the hypersomnolence market, which represents a 'completely new commercial domain' for them. Other industry leaders are adopting platforms like Salesforce Life Sciences Cloud to scale engagement across clinical, medical, and commercial data.

Finance: draft 13-week cash view by Friday.

Centessa Pharmaceuticals plc (CNTA) - Canvas Business Model: Customer Segments

You're looking at the core groups Centessa Pharmaceuticals plc targets with its pipeline, especially its orexin receptor 2 (OX2R) agonist franchise, which includes ORX750 for sleep-wake disorders.

Patients with chronic sleep-wake disorders: Narcolepsy Type 1, Narcolepsy Type 2, and Idiopathic Hypersomnia.

The addressable patient pool for Centessa Pharmaceuticals plc's lead candidate, ORX750, is substantial, focusing on conditions like Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), and Idiopathic Hypersomnia (IH).

• Estimated U.S. population with narcolepsy: approximately 1 in every 2,000 people.
• Total estimated U.S. patients: around 200,000 Americans.
• Total estimated worldwide patients: approximately 3 million people.
• A 2018 German study estimated narcolepsy diagnostic prevalence at 17.88 per 100,000 persons.
• In a patient survey, nearly 48% were diagnosed with NT1.

Neurologists and sleep specialists who prescribe novel therapies.

These are the prescribers who will evaluate Centessa Pharmaceuticals plc's data, particularly from the Phase 2a CRYSTAL-1 study for ORX750 across NT1, NT2, and IH indications. Specialists are looking for potential best-in-class OX2R agonists that can restore normative wakefulness.

Metric	Data Point
ORX750 Study Status (as of Q2 2025)	Phase 2a CRYSTAL-1 ongoing across NT1, NT2, and IH
Expected Data Readouts (2025)	Data expected across all three indications (NT1, NT2, IH)
Potential First-in-Class Target	NT2 and IH

Large pharmaceutical companies seeking to license or acquire late-stage assets.

Potential acquirers assess the value of Centessa Pharmaceuticals plc's pipeline, which includes ORX750, ORX142, and the LockBody technology platform. The company's recent financing activity signals a push to advance these assets toward registrational studies.

• Market Capitalization (as of November 14, 2025): $4.08B.
• Stock Price (as of November 14, 2025): $27.61.
• Recent Capital Raise (November 2025): Approximately US$250 million in a follow-on equity offering.
• Cash Position (as of June 30, 2025): $404.1 million.
• Trailing 12-Month Revenue (as of September 30, 2025): $15M.

Institutional investors and venture capital firms funding high-risk, high-reward biotech.

This segment includes the existing base, such as General Atlantic, Vida Ventures, and Janus Henderson Investors from the initial Series A round of $250M in February 2021, and newer participants from the late 2025 equity raise. These investors are betting on the company's ability to execute on its pipeline while managing its current burn rate.

Financial Metric (as of latest report)	Value
Net Loss Q2 2025	$50.3 million
Cash as of March 31, 2025	$424.9 million
Institutional Ownership Percentage (Q1 data)	82.01%
Total Funding Raised (to date)	$250M in 1 round (Series A)

The company expects its cash position as of June 30, 2025, to fund operations into mid-2027.

Centessa Pharmaceuticals plc (CNTA) - Canvas Business Model: Cost Structure

You're looking at the core spending that fuels Centessa Pharmaceuticals plc's pipeline progression, which is heavily weighted toward discovery and development. Honestly, for a clinical-stage biotech, the cost structure is almost entirely dictated by the science.

Research & Development (R&D) expenses are definitely the primary cost driver, totaling $41.6 million in Q3 2025. That number is up from $33.9 million in the same quarter last year, showing the ramp-up in clinical activities, especially with the ORX750 Phase 2a study ongoing. This spending funds the clinical trials, lab work, and the people running those complex programs.

You're also dealing with high fixed costs associated with clinical trial execution and manufacturing scale-up. These aren't costs that drop just because you have a slow month; running a trial with 89 volunteers, like the ORX142 Phase 1 study, requires consistent, significant spending on site fees, monitoring, and supply chain setup. It's the nature of the beast in pharma development.

Here's a quick look at the key expense components from the latest reporting period:

Cost Metric	Q3 2025 Amount	Year-to-Date (YTD) 2025 Amount	Prior Year Q3 Comparison (R&D)
Research & Development (R&D) Expenses	$41.6 million	$117.7 million	$33.9 million (Q3 2024)
General & Administrative (G&A) Expenses	$12.2 million	$36.5 million	$12.5 million (Q3 2024)
Net Cash Used in Operations (YTD)	N/A	$(138.0) million	$(99.3) million (YTD 2024)

General and Administrative (G&A) expenses were $12.2 million in Q3 2025. That reflects a lean corporate structure, especially when you compare it to the R&D spend. You see G&A staying relatively flat or even slightly decreasing year-over-year, which is a good sign of cost discipline at the corporate level.

The company anticipates future increases in G&A, which will likely include costs associated with maintaining compliance as a public company, plus fees for outside consultants, lawyers, and accountants. This ties into the need for significant capital expenditure on intellectual property maintenance and licensing fees, though specific IP maintenance dollar amounts aren't broken out separately from general operating costs.

The cost management strategy is clearly focused on extending the runway. As of September 30, 2025, Centessa Pharmaceuticals plc held $349.0 million in cash, cash equivalents, and investments. Management expects this cash position to fund operations into mid-2027 based on current operating plans.

Key cost considerations include:

• The R&D spend is directly tied to advancing the OX2R agonist pipeline.
• The YTD R&D expense of $117.7 million shows the cumulative investment pressure.
• The company reported an annual interest expense of $8.7 million YTD on its term loan.
• The net loss for Q3 2025 was $54.9 million.

Finance: draft 13-week cash view by Friday.

Centessa Pharmaceuticals plc (CNTA) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of Centessa Pharmaceuticals plc as of late 2025, and honestly, it's a classic biotech story right now: funding the pipeline through non-operating income while waiting for the main event.

Non-product revenue from upfront payments and milestones is the most concrete income stream recognized so far this year. For the six months ended June 30, 2025, Centessa Pharmaceuticals plc reported $15,000 thousand, or $15.0 million, in license and other revenue. This was the upfront payment recognized in Q1 2025 related to the license agreement for its proprietary LockBody platform with Genmab A/S, which was executed on February 14, 2025. This type of revenue is non-recurring and should be modeled as such unless another business development event occurs.

The potential for future non-product revenue is significant, tied directly to the success of partnered programs. The Genmab agreement is a prime example of this structure, which is common for a company at this stage. Here's a quick look at the potential value unlocked by that single deal:

• Option exercise fees potentially totaling up to an additional $15 million.
• Eligibility for potential payouts of approximately $230 million in development, regulatory, and sales milestones per product.
• Tiered royalties ranging in the mid-single digits on annual global net licensed product sales.

To be fair, the company is still entirely dependent on these financing and partnership events because Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. This means there is zero revenue from product sales as of late 2025; the company remains pre-revenue from product sales and continues to report significant net losses and a large accumulated deficit.

Given the high cash burn associated with advancing its pipeline, the primary funding source is equity financing, which has recently been substantial to shore up the balance sheet. Centessa Pharmaceuticals plc completed a significant follow-on public offering in November 2025, raising approximately $250 million. This offering involved American Depositary Shares sold at $21.50 each. This capital injection boosted cash reserves to around $619 million, which management stated provides funding clarity into mid-2027 under current plans. This financing activity is critical to supporting the advancement of the ORX750 program into pivotal clinical trials.

Here's a summary mapping the key financial components that currently constitute Centessa Pharmaceuticals plc's cash inflow strategy:

Revenue/Financing Type	Specific Amount/Range	Recognition/Status
Recognized License Revenue (Q1 2025)	$15.0 million	Recognized upfront payment from Genmab deal
Potential Future Milestones (Genmab)	Up to approx. $230 million per product	Contingent upon development/regulatory/sales success
Recent Equity Financing (Nov 2025)	$250.0 million	Completed follow-on public offering
Total Stated Liquidity (June 30, 2025)	$404.1 million	Cash, cash equivalents, and investments before Nov 2025 raise
Existing Financing Facility	Up to $125.0 million	At-The-Market (ATM) Program capacity

What this estimate hides is that the $250 million raise, while necessary, also means current shareholders have experienced dilution. Finance: draft 13-week cash view by Friday.